Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca's ovarian cancer drug Lynparza demonstrates PFS benefit as maintenance therapy in Phase

firstwordpharmaMarch 15, 2017

Tag: maintenance therapy , ovarian cancer

PharmaSources Customer Service